Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • DCGI to design vaccine...

    DCGI to design vaccine specific regulatory policy

    Written by Ruby Khatun Khatun Published On 2018-05-22T15:07:08+05:30  |  Updated On 22 May 2018 3:07 PM IST

    Hyderabad: Soon the country will get a new policy specifically for vaccines as the Drugs Controller General of India, S. Eswara Reddy has announced his plans to this effect. DCGI plans to come out with vaccine-specific regulatory policy along with a manual for regulatory requirements for commercialization of new drug and on how to conduct clinical trials in India.


    DCGI said that since pneumococcal is one of the major priority vaccines, they would first come out a policy to facilitate introducing the indigenously-produced vaccine.


    Speaking at a symposium on 'research and development of vaccines: issues, challenges and opportunities' organized by PC2 Scientific Services, a strategic and technical consulting company in association with Federation of Asian Biotech Associations (FABA) and CR RAO AIMSCS at University of Hyderabad, he listed out the steps being taken by his organisation to promote innovation through transparent system and regulatory changes.


    The symposium was attended by delegates from scientific research and academic and industry both from India and abroad and Manuel Elkin Patarroyo, the malaria vaccine scientist from Columbia, was the keynote speaker at the symposium.


    Stating that they were also in process of making new regulations for conducting clinical trials and new drugs DCGI told IANS, “We will fix timelines. 30 days will be maximum timeline for giving response to their applications. If response is not received within 30 days, the application will be deemed approved.”

    DCGI also proposed to conduct symposiums across India and invite research institutions to know their regulatory challenges. The regulator will reach out to research and innovation centres by disseminating information about the regulatory requirements for commercialization of their products.

    At the symposium, Reddy underlined the need to communicate to media the facts about the deaths due to clinical trials and told the gathering that media gives a wrong projection about the number of deaths.

    He said media reports that during last 7-8 years, 25,000 patients died during clinical trials in India while the fact is that only 5 percent of these deaths are actually due to clinical trials. "For example, during clinical trials related to cancer, patients who are already in terminal stage die. The death of such patients is not due to clinical trials," he said.

    Director of PC2 Scientific Services, Dr. Dasari V Ravi Kumar said that Hyderabad is producing about 33 percent of global vaccines dosages and 35 percent to the pharmaceutical products in the country.
    clinical trialsDCGIdrug policyDrugs Controller General of IndiaFederation of Asian Biotech AssociationsIndiaPC2 Scientific ServicesPneumococcalS Eswara Reddysymposiumvaccinevaccine specific regulatory policy
    Source : with inputs from IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok